Elanco Animal Health (ELAN) reported a proposed sale of 49,333 shares of common stock through UBS on the NYSE with an aggregate market value of $830,000, representing approximately 0.01% of the 496,646,504 shares outstanding. The filing lists the acquisition history: 1,536 shares on 12/03/2020, 16,738 shares on 02/22/2021, and 31,059 shares on 02/22/2022, all identified as stock awards.
The notice indicates no securities sold in the past three months and includes the signatory's representation that they do not know any material nonpublic information about the issuer. The form references Rule 144 procedures and mentions Rule 10b5-1 plan disclosure but does not provide a plan adoption or instruction date.
Elanco (ELAN) Q2 2025 10-Q highlights:
- Revenue rose 4.8% YoY to $1.24 bn; pet-health up 11% to $643 m, offsetting the divested aqua unit (zero vs $49 m).
- Gross margin held at 57.4% (713 m/1,241 m).
- Operating profile: SG&A climbed 13% to $400 m; R&D up 3% to $92 m; special charges plunged to $1 m from $80 m, driving a swing to positive pretax income of $25 m (-$32 m LY).
- Net income $11 m vs -$50 m; diluted EPS $0.02 vs -$0.10.
- Six-month totals: revenue +1.9% to $2.43 bn; net income $78 m vs -$18 m.
- Cash flow: operating cash +15% to $233 m; FCF negative as capex doubled to $122 m (new HQ).
- Balance sheet: cash $539 m (+$71 m YTD); total debt trimmed to $3.95 bn (ex-lease) from $4.32 bn; however a new $255 m finance lease and $293 m liability tied to royalty sale raise fixed commitments.
- Inventory up 6% YoY to $1.67 bn; accounts receivable +23%.
- Leverage: ~4.1× EBITDA remains high but 89% of debt is fixed; interest expense down 26% YoY.
- Strategic moves: • Closed $295 m royalty monetization with Blackstone (16.1% implied IRR). • HQ lease in Indianapolis (option to buy at $250 m in 2030). • Continued rollout of Zenrelia, Credelio Quattro, Bovaer; EU Zenrelia approval in Jul-25.
- Guidance not updated in filing.
Key takeaways: Return to profitability aided by lower one-offs and interest expense; pet-health momentum strong. Balance-sheet de-risking continues, but inventory build, rising SG&A and new fixed obligations temper the improvement.